Trevi Therapeutics (NASDAQ:TRVI) used its fourth-quarter and year-end 2025 earnings call to outline next steps following what management described as a pivotal year driven by positive clinical data in two chronic cough programs. President and CEO Jennifer Good said 2025 marked a “major inflection point” for the company after favorable readouts from the CORAL trial […]

Ovid Therapeutics (NASDAQ:OVID) outlined new pipeline and financing updates alongside its fourth-quarter and full-year 2025 results, highlighting regulatory clearance in Australia for its KCC2 direct activator OV4071, new safety and tolerability data for its seizure candidate OV329, and a $60 million PIPE financing led by Point72. PIPE financing, warrant trigger, and cash runway Management said […]

CytomX Therapeutics (NASDAQ:CTMX) outlined updated Phase 1 dose expansion results for its EpCAM-targeting Probody antibody-drug conjugate (ADC) varsetatug masetecan (Varseta-M, “Varseta”) during a conference call covering 2025 financial results and new clinical data. Management emphasized that the call’s primary focus was Varseta’s late-line metastatic colorectal cancer (CRC) data and the company’s evolving strategy for dose […]